Moderna Cancer Vaccine Data Confirms 42% Recurrence Cut
Moderna cancer vaccine data confirms a 42% cut in melanoma recurrence risk, but an ESMO embargo breach triggered wild swings in MRNA shares.
Topic
biotech
Every Financial News story tagged biotech, newest first.
- Stories
- 13
- Last updated
- Follow
- RSS feed
Moderna stock plunges 25% after melanoma vaccine data leak
A melanoma vaccine data leak wiped $24bn off Moderna before its Madrid presentation, despite a statistically strong Phase 3 result.
Gilead’s UC Pill Hits Trial Goal, Stock Still Slips
Gilead's ulcerative colitis trial met its main goal, but GILD shares fell 1.42% as RBC said the readout was unlikely to move…
More in biotech
1–10 of 13
Adlai Nortye lines up Lilly, Merck KGaA for AN4035 trial
Adlai Nortye clinical collaboration with Lilly and Merck KGaA will test AN4035 plus cetuximab, as ANL shares trade 26% below their 20-day high.
Nvidia-Backed Iambic Therapeutics Files for Nasdaq IPO as ‘IAM’
Iambic Therapeutics, backed by Nvidia and Qatar's sovereign fund, has filed for a Nasdaq IPO under ticker IAM to fund cancer drug trials.
FDA Approves Ionis’s Zanvastro for Alexander Disease
FDA approves Zanvastro, the first Alexander disease treatment, from Ionis Pharmaceuticals - but shares barely move on the news.
Revolution Medicines Wins FDA Pancreatic Cancer Drug Approval
The FDA's pancreatic cancer drug approval for Revolution Medicines' daraxonrasib lands months early, but the stock barely moved. Here's why.
Changpeng Zhao Navigating Life After Legal Battles
Changpeng Zhao, the brains behind Binance, has recently emerged from a four-month imprisonment. This pivotal moment marks a new chapter for the former CEO.His incarceration stemmed from anti-money laundering charges,…
CardiaTec Secures $6.5M to Transform Cardiovascular Drug Discovery
CardiaTec has made significant strides in cardiovascular research, recently obtaining $6.5 million in seed funding. This investment marks a major step forward in their quest to transform cardiovascular drug discovery.Strategic…
NADMED Raises $3.5M for Advanced NAD Testing Kits
NADMED, a pioneering Finnish biotech startup, has secured $3.5 million in Series A funding, marking a pivotal moment in the field of medical biotechnology. The investment is expected to propel…
Page 1 of 2